Compare Inovio Pharmaceuticals Inc (INO) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs KB Financial Group, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $89.27M), while KB Financial Group, Inc. trades at $115.25 (market cap $38.56B). The key difference: KB Financial Group, Inc. is far larger — about 431.9× Inovio Pharmaceuticals Inc's market cap, and KB Financial Group, Inc. pays a 2.72% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | KB | |
|---|---|---|
Market Cap | $89.27M | $38.56B |
Sector | Health | Financials |
52-Week High | $2.87 | $123.25 |
52-Week Low | $1.05 | $77.50 |
Enterprise Value | $60.28M | — |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.
The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.
KB trades at $120.09, up 0.6% with a bullish technical trend and strong earnings momentum, beating estimates for three consecutive quarters. Revenue grew to $21.23T in 2025 with net income margin expanding to 27.82%. The stock shows solid valuation metrics with P/E of 11.07 and P/B of 1.05, while analyst sentiment is mixed with 33% buy ratings amid ongoing diversification into non-banking segments.
The outlook remains positive given consistent earnings beats and ROE expansion potential, though risks include heavy investing cash outflows and reliance on non-banking growth. Institutional hold ratings suggest cautious optimism, with the stock positioned for stability if diversification succeeds but vulnerable to sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
